Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARTIVION, INC.AORT · Entity 4767 | SVP, Clinical & MD Affair | March 02, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARTIVION, INC.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,097 |
Ending reported balance
After 2026-03-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-02 · Grant · Acquired 21,838 · Balance 62,246 F1: Represents performance stock units granted on February 28, 2025. One third (1/3) were issued on March 2, 2026. The remaining shares earned in connection with the February 2025 grant will be eligible to vest and be issued as follows: one third (1/3) on February 28, 2027; and one third (1/3) on February 28, 2028, assuming employment on the relevant vesting date. Row 2 · 2026-03-03 · Sale · Disposed 2,149 · Balance 60,097 F2: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents performance stock units granted on February 28, 2025. One third (1/3) were issued on March 2, 2026. The remaining shares earned in connection with the February 2025 grant will be eligible to vest and be issued as follows: one third (1/3) on February 28, 2027; and one third (1/3) on February 28, 2028, assuming employment on the relevant vesting date.
F2: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2026 Filed Mar 4, 2026 23:51 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 2,149 | $37.78 | $81,179.76 |
DisclosureSEC source: 0001628280-26-014894 · wk-form4_1772668260.xml · nonDerivative · entry 2 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,097 F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 20:04 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 1,513 | $38.02 | $57,531.67 |
DisclosureSEC source: 0001628280-26-013690 · wk-form4_1772568267.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,408 F1 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:51 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 21,838 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014894 · wk-form4_1772668260.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,246 F1 · shares: Represents performance stock units granted on February 28, 2025. One third (1/3) were issued on March 2, 2026. The remaining shares earned in connection with the February 2025 grant will be eligible to vest and be issued as follows: one third (1/3) on February 28, 2027; and one third (1/3) on February 28, 2028, assuming employment on the relevant vesting date. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 22:36 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 1,259 | $35.69 | $44,937.49 |
DisclosureSEC source: 0001628280-26-011837 · wk-form4_1772058983.xml · nonDerivative · entry 2 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,921 F2 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 22:36 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 2,423 | $37.59 | $91,075.72 |
DisclosureSEC source: 0001628280-26-011837 · wk-form4_1772058983.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,180 F1 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| December 31, 2025 Filed Jan 28, 2026 20:53 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 316 | $26.14 | $8,259.61 |
DisclosureSEC source: 0001628280-26-003824 · wk-form5_1769633614.xml · nonDerivative · entry 2 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,603 F1 · price: These shares were acquired pursuant to Artivion Inc.'s Employee Stock Purchase Plan (ESPP). The shares were acquired in transactions exempt pursuant to 16b-3. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:23 UTC | ARTIVION, INC. AORT · Entity 4767 | Exercise / conversionStock Options (Right to buy) · Derivative | 27,075 | $0.00 Strike: $11.03 | $0.00 |
DisclosureSEC source: 0001628280-25-053859 · wk-form4_1764023022.xml · derivative · entry 8 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,075 shares Expires 2029-11-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was November 8, 2023. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:23 UTC | ARTIVION, INC. AORT · Entity 4767 | Exercise / conversionStock Options (Right to buy) · Derivative | 20,301 | $0.00 Strike: $18.44 | $0.00 |
DisclosureSEC source: 0001628280-25-053859 · wk-form4_1764023022.xml · derivative · entry 7 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,301 shares Expires 2029-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was February 23, 2023. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:23 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 8,370 | $45.35 | $379,537.65 |
DisclosureSEC source: 0001628280-25-053859 · wk-form4_1764023022.xml · nonDerivative · entry 6 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,753 F4 · price: Reflects weighted average price. Range of prices were between $45.26 to $45.53. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:23 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 18,705 | $44.91 | $840,041.55 |
DisclosureSEC source: 0001628280-25-053859 · wk-form4_1764023022.xml · nonDerivative · entry 5 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,123 F3 · price: Reflects weighted average price. Range of prices were between $44.26 to $45.255. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:23 UTC | ARTIVION, INC. AORT · Entity 4767 | Exercise / conversionCommon Stock | 27,075 | $11.03 | $298,637.25 |
DisclosureSEC source: 0001628280-25-053859 · wk-form4_1764023022.xml · nonDerivative · entry 4 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:23 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 5,715 | $45.35 | $259,152.39 |
DisclosureSEC source: 0001628280-25-053859 · wk-form4_1764023022.xml · nonDerivative · entry 3 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,753 F2 · price: Reflects weighted average price. Range of prices were between $45.26 to $45.54. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:23 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 14,586 | $44.92 | $655,188.53 |
DisclosureSEC source: 0001628280-25-053859 · wk-form4_1764023022.xml · nonDerivative · entry 2 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,468 F1 · price: Reflects weighted average price. Range of prices were between $44.26 to $45.25. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 22:23 UTC | ARTIVION, INC. AORT · Entity 4767 | Exercise / conversionCommon Stock | 20,301 | $18.44 | $374,350.44 |
DisclosureSEC source: 0001628280-25-053859 · wk-form4_1764023022.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 14:35 UTC | ARTIVION, INC. AORT · Entity 4767 | Exercise / conversionStock Options (Right to buy) · Derivative | 1,355 | $0.00 Strike: $11.03 | $0.00 |
DisclosureSEC source: 0001628280-25-053702 · wk-form4_1763994956.xml · derivative · entry 7 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,075 Underlying: Common Stock · 1,355 shares Expires 2029-11-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was November 8, 2023. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 14:35 UTC | ARTIVION, INC. AORT · Entity 4767 | Exercise / conversionStock Options (Right to buy) · Derivative | 2,033 | $0.00 Strike: $18.44 | $0.00 |
DisclosureSEC source: 0001628280-25-053702 · wk-form4_1763994956.xml · derivative · entry 6 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,301 Underlying: Common Stock · 2,033 shares Expires 2029-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was February 23, 2023. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 14:35 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 1,355 | $44.28 | $59,996.69 |
DisclosureSEC source: 0001628280-25-053702 · wk-form4_1763994956.xml · nonDerivative · entry 5 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,753 F3 · price: Reflects weighted average price. Range of prices were between $44.26 to $44.35. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 14:35 UTC | ARTIVION, INC. AORT · Entity 4767 | Exercise / conversionCommon Stock | 1,355 | $11.03 | $14,945.65 |
DisclosureSEC source: 0001628280-25-053702 · wk-form4_1763994956.xml · nonDerivative · entry 4 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 14:35 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 2,033 | $44.32 | $90,092.40 |
DisclosureSEC source: 0001628280-25-053702 · wk-form4_1763994956.xml · nonDerivative · entry 3 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,753 F2 · price: Reflects weighted average price. Range of prices were between $44.26 to $44.44. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 14:35 UTC | ARTIVION, INC. AORT · Entity 4767 | Exercise / conversionCommon Stock | 2,033 | $18.44 | $37,488.52 |
DisclosureSEC source: 0001628280-25-053702 · wk-form4_1763994956.xml · nonDerivative · entry 2 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 14:35 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 11,888 | $44.14 | $524,736.32 |
DisclosureSEC source: 0001628280-25-053702 · wk-form4_1763994956.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,753 F1 · price: Reflects weighted average price. Range of prices were between $43.92 to $44.49. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 17:07 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 4,993 | $45.86 | $228,968.99 |
DisclosureSEC source: 0001628280-25-052260 · wk-form4_1763140046.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,641 F1 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| November 10, 2025 Filed Nov 13, 2025 01:05 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 2,566 | $44.62 | $114,492.35 |
DisclosureSEC source: 0001628280-25-051789 · wk-form4_1762995941.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,634 F1 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 22:08 UTC | ARTIVION, INC. AORT · Entity 4767 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,200 | $0.00 Strike: $11.03 | $0.00 |
DisclosureSEC source: 0001849615-25-000003 · wk-form4_1756418919.xml · derivative · entry 3 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,200 shares Expires 2029-11-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was November 8, 2023. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 22:08 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 18,200 | $44.02 | $801,218.60 |
DisclosureSEC source: 0001849615-25-000003 · wk-form4_1756418919.xml · nonDerivative · entry 2 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,200 F1 · price: Reflects weighted average price. Range of prices were between $43.84 to $44.26. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 22:08 UTC | ARTIVION, INC. AORT · Entity 4767 | Exercise / conversionCommon Stock | 18,200 | $11.03 | $200,746.00 |
DisclosureSEC source: 0001849615-25-000003 · wk-form4_1756418919.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2025 Filed Jan 28, 2026 20:53 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 534 | $24.30 | $12,977.27 |
DisclosureSEC source: 0001628280-26-003824 · wk-form5_1769633614.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,287 F1 · price: These shares were acquired pursuant to Artivion Inc.'s Employee Stock Purchase Plan (ESPP). The shares were acquired in transactions exempt pursuant to 16b-3. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 15:48 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 1,236 | $29.50 | $36,462.00 |
DisclosureSEC source: 0000784199-25-000133 · wk-form4_1750261700.xml · nonDerivative · entry 2 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,200 F1 · shares: The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on March 14, 2025. F2 · price: Reflects the price the shares were sold. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 15:48 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 13,764 | $29.50 | $406,038.00 |
DisclosureSEC source: 0000784199-25-000133 · wk-form4_1750261700.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,436 F1 · shares: The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on March 14, 2025. F2 · price: Reflects the price the shares were sold. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 00:22 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 1,826 | $28.43 | $51,908.98 |
DisclosureSEC source: 0000784199-25-000131 · wk-form4_1750119734.xml · nonDerivative · entry 4 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,200 F1 · shares: The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on March 14, 2025. F3 · price: Reflects weighted average price for Employee Stock Purchase Plan. Range of prices were between $28.18 to $28.65. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 00:22 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 14,306 | $28.42 | $406,600.84 |
DisclosureSEC source: 0000784199-25-000131 · wk-form4_1750119734.xml · nonDerivative · entry 3 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,026 F1 · shares: The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on March 14, 2025. F4 · price: Reflects weighted average price for Performance Stock Units. Range of prices were between $28.17 to $28.675. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 00:22 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 1,253 | $28.47 | $35,668.65 |
DisclosureSEC source: 0000784199-25-000131 · wk-form4_1750119734.xml · nonDerivative · entry 2 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,332 F1 · shares: The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on March 14, 2025. F3 · price: Reflects weighted average price for Employee Stock Purchase Plan. Range of prices were between $28.18 to $28.65. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 00:22 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 8,747 | $28.46 | $248,952.74 |
DisclosureSEC source: 0000784199-25-000131 · wk-form4_1750119734.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,585 F1 · shares: The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on March 14, 2025. F2 · price: Reflects weighted average price for Performance Stock Units. Range of prices were between $28.175 to $28.69. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 09, 2025 Filed May 12, 2025 18:31 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 4,811 | $29.13 | $140,145.39 |
DisclosureSEC source: 0000784199-25-000076 · wk-form4_1747074683.xml · nonDerivative · entry 2 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,332 F2 · price: Reflects weighted average price for Performance Stock Units. Range of prices were between $28.97 to $29.25. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 09, 2025 Filed May 12, 2025 18:31 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 5,737 | $29.13 | $167,119.96 |
DisclosureSEC source: 0000784199-25-000076 · wk-form4_1747074683.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,143 F1 · price: Reflects weighted average price for Restricted Stock Units. Range of prices were between $28.97 to $29.25. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 21:03 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 1,603 | $24.80 | $39,761.13 |
DisclosureSEC source: 0000784199-25-000049 · wk-form4_1741640586.xml · nonDerivative · entry 2 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,880 F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 21:03 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 19,240 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-25-000049 · wk-form4_1741640586.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,483 F1 · shares: Represents performance stock units granted on February 23, 2024. One third (1/3) were issued on March 6, 2025. The remaining shares earned in connection with the February 2024 grant will be eligible to vest and be issued as follows: one third (1/3) on February 23, 2026; and one third (1/3) on February 23, 2027, assuming employment on the relevant vesting date. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 20:08 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 18,398 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-25-000041 · wk-form4_1741118887.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,243 F1 · shares: Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 18:46 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 1,246 | $27.31 | $34,023.28 |
DisclosureSEC source: 0000784199-25-000014 · wk-form4_1740595575.xml · nonDerivative · entry 4 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,845 F1 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 18:46 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 672 | $27.31 | $18,349.63 |
DisclosureSEC source: 0000784199-25-000014 · wk-form4_1740595575.xml · nonDerivative · entry 3 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,091 F1 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 18:46 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 470 | $27.31 | $12,833.82 |
DisclosureSEC source: 0000784199-25-000014 · wk-form4_1740595575.xml · nonDerivative · entry 2 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,763 F1 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 18:46 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 2,299 | $27.31 | $62,776.49 |
DisclosureSEC source: 0000784199-25-000014 · wk-form4_1740595575.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,233 F1 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| December 31, 2024 Filed Jan 30, 2025 15:13 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 381 | $21.63 | $8,241.03 |
DisclosureSEC source: 0000784199-25-000004 · wk-form5_1738249991.xml · nonDerivative · entry 2 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,532 F1 · price: These shares were acquired pursuant to Artivion Inc.'s Employee Stock Purchase Plan (ESPP). The shares were acquired in transactions exempt pursuant to 16b-3. Read SEC document |
| June 30, 2024 Filed Jan 30, 2025 15:13 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 855 | $15.20 | $12,996.00 |
DisclosureSEC source: 0000784199-25-000004 · wk-form5_1738249991.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,151 F1 · price: These shares were acquired pursuant to Artivion Inc.'s Employee Stock Purchase Plan (ESPP). The shares were acquired in transactions exempt pursuant to 16b-3. Read SEC document |
| March 20, 2024 Filed Mar 21, 2024 21:14 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 2,183 | $20.39 | $44,511.37 |
DisclosureSEC source: 0000784199-24-000164 · wk-form4_1711055634.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,296 F1 · shares: These shares were sold upon the vesting of Restricted Stock awards to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 23:05 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 1,506 | $18.72 | $28,195.48 |
DisclosureSEC source: 0000784199-24-000096 · wk-form4_1709852706.xml · nonDerivative · entry 2 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,438 F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
| March 01, 2024 Filed Mar 7, 2024 23:05 UTC | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 5,724 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-24-000096 · wk-form4_1709852706.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,944 F1 · shares: Represents LTIP performance stock units of which one hundred percent (100%) were issued on March 1, 2024. Read SEC document |
| March 01, 2024 Filed Mar 15, 2024 00:06 UTC Amendment | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 1,506 | $18.72 | $28,195.48 |
DisclosureSEC source: 0000784199-24-000128 · wk-form4a_1710461203.xml · nonDerivative · entry 2 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,479 F3 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. F2 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4. Read SEC document |
| March 01, 2024 Filed Mar 15, 2024 00:06 UTC Amendment | ARTIVION, INC. AORT · Entity 4767 | GrantCommon Stock | 5,724 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-24-000128 · wk-form4a_1710461203.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,985 F1 · shares: Represents LTIP performance stock units of which one hundred percent (100%) were issued on March 1, 2024. F2 · balance_after: As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:18 UTC | ARTIVION, INC. AORT · Entity 4767 | SaleCommon Stock | 465 | $19.83 | $9,223.00 |
DisclosureSEC source: 0000784199-24-000076 · wk-form4_1709245096.xml · nonDerivative · entry 1 Stanton Marshall S. · CIK 0001849615 · SVP, Clinical & MD Affair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,220 F1 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.